This article was originally published in RAJ Devices
International standard developers agree common policy on use of patents
You may also be interested in...
The company has come a long way since gene therapy flop Glybera, and claims best-in-class status for viral vector.
Softening provisions to make EU-wide joint clinical assessments voluntary would make proposed legislation on HTA cooperation redundant, says Eurordis.